Bausch Health Cos (BHC) Competitors

Bausch Health Cos logo
$8.46 +0.04 (+0.42%)
As of 01:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BHC vs. RDY, CORT, AXSM, LNTH, and AMRX

Should you buy Bausch Health Cos stock or one of its competitors? Bausch Health Cos's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Lantheus (LNTH), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bausch Health Cos compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 8.56% compared to Bausch Health Cos' net margin of -7.57%. Dr. Reddy's Laboratories' return on equity of 7.91% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories8.56% 7.91% 5.29%
Bausch Health Cos -7.57%-401.73%7.34%

In the previous week, Bausch Health Cos had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Bausch Health Cos and 2 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.69 beat Bausch Health Cos' score of 0.62 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dr. Reddy's Laboratories presently has a consensus price target of $492.90, indicating a potential upside of 3,251.92%. Bausch Health Cos has a consensus price target of $8.75, indicating a potential upside of 3.98%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B3.43$456M$0.3739.74
Bausch Health Cos$10.27B0.31$157M-$2.29N/A

Summary

Dr. Reddy's Laboratories beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Corcept Therapeutics?

Bausch Health Cos (NYSE:BHC) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Corcept Therapeutics has a net margin of 16.53% compared to Bausch Health Cos' net margin of -7.57%. Corcept Therapeutics' return on equity of 22.56% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Cos-7.57% -401.73% 7.34%
Corcept Therapeutics 16.53%22.56%17.83%

Bausch Health Cos has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bausch Health Cos has higher revenue and earnings than Corcept Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Cos$10.27B0.31$157M-$2.29N/A
Corcept Therapeutics$761.41M9.95$99.65M$1.2754.50

In the previous week, Bausch Health Cos and Bausch Health Cos both had 4 articles in the media. Corcept Therapeutics' average media sentiment score of 0.88 beat Bausch Health Cos' score of 0.62 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bausch Health Cos presently has a consensus target price of $8.75, indicating a potential upside of 3.98%. Corcept Therapeutics has a consensus target price of $139.50, indicating a potential upside of 101.53%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Corcept Therapeutics beats Bausch Health Cos on 13 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to Axsome Therapeutics?

Bausch Health Cos (NYSE:BHC) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Bausch Health Cos has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Bausch Health Cos has a net margin of -7.57% compared to Axsome Therapeutics' net margin of -18.18%. Axsome Therapeutics' return on equity of -198.73% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Cos-7.57% -401.73% 7.34%
Axsome Therapeutics -18.18%-198.73%-22.03%

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bausch Health Cos presently has a consensus target price of $8.75, indicating a potential upside of 3.98%. Axsome Therapeutics has a consensus target price of $266.21, indicating a potential upside of 94.30%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Axsome Therapeutics had 18 more articles in the media than Bausch Health Cos. MarketBeat recorded 22 mentions for Axsome Therapeutics and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.62 beat Axsome Therapeutics' score of 0.22 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
2 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Bausch Health Cos has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Cos$10.27B0.31$157M-$2.29N/A
Axsome Therapeutics$638.50M11.29-$183.17M-$3.06N/A

Summary

Axsome Therapeutics beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Lantheus has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.54B4.32$233.56M$4.0625.05
Bausch Health Cos$10.27B0.31$157M-$2.29N/A

Lantheus has a net margin of 17.28% compared to Bausch Health Cos' net margin of -7.57%. Lantheus' return on equity of 29.26% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus17.28% 29.26% 15.40%
Bausch Health Cos -7.57%-401.73%7.34%

Lantheus has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Lantheus currently has a consensus target price of $107.44, suggesting a potential upside of 5.63%. Bausch Health Cos has a consensus target price of $8.75, suggesting a potential upside of 3.98%. Given Lantheus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lantheus is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

99.1% of Lantheus shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lantheus had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Bausch Health Cos. Lantheus' average media sentiment score of 0.67 beat Bausch Health Cos' score of 0.62 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Lantheus beats Bausch Health Cos on 13 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Amneal Pharmaceuticals. Bausch Health Cos is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$3.02B2.25$72.06M$0.4250.55
Bausch Health Cos$10.27B0.31$157M-$2.29N/A

Amneal Pharmaceuticals presently has a consensus target price of $23.00, suggesting a potential upside of 8.34%. Bausch Health Cos has a consensus target price of $8.75, suggesting a potential upside of 3.98%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Amneal Pharmaceuticals is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

Amneal Pharmaceuticals has a net margin of 4.17% compared to Bausch Health Cos' net margin of -7.57%. Amneal Pharmaceuticals' return on equity of 283.50% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Amneal Pharmaceuticals4.17% 283.50% 7.79%
Bausch Health Cos -7.57%-401.73%7.34%

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Bausch Health Cos. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.62 beat Amneal Pharmaceuticals' score of 0.53 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amneal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amneal Pharmaceuticals beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHC vs. The Competition

MetricBausch Health CosPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$3.15B$13.63B$7.76B$22.96B
Dividend YieldN/A2.58%2.46%3.79%
P/E Ratio-3.6729.4734.2929.23
Price / Sales0.317.018.483.29
Price / Cash1.1315.7421.9315.51
Price / Book-9.295.114.393.63
Net Income$157M$2.88B$3.51B$1.08B
7 Day Performance1.81%-3.90%-5.19%-3.22%
1 Month Performance34.10%-4.91%-4.33%-1.96%
1 Year Performance37.88%-7.41%-1.33%6.74%

Bausch Health Cos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHC
Bausch Health Cos
2.2183 of 5 stars
$8.46
+0.4%
$8.75
+3.5%
+34.1%$3.15B$10.27BN/A20,300
RDY
Dr. Reddy's Laboratories
3.3871 of 5 stars
$15.03
+0.8%
$492.90
+3,178.8%
+5.5%$12.33B$3.58B40.6327,527
CORT
Corcept Therapeutics
3.8952 of 5 stars
$75.03
+3.1%
$139.50
+85.9%
-8.4%$8.67B$761.41M62.38730
AXSM
Axsome Therapeutics
3.5141 of 5 stars
$133.96
+1.2%
$267.58
+99.7%
-1.9%$7.21B$638.50MN/A925
LNTH
Lantheus
2.4337 of 5 stars
$101.01
+0.4%
$107.44
+6.4%
+91.9%$6.60B$1.54B20.311,193

Related Companies and Tools


This page (NYSE:BHC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners